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Abstract 
The neuropeptide oxytocin (OXT) is well-known for its role in pregnancy and lactation. 
However, its role extends beyond the reproductive system. In fact, the role of OXT in 
neuropsychiatric disorders has long been studied. OXT is largely associated with social    
behavior and stress reduction, and so it is to no surprise that it is thought to be involved in         
the pathophysiology of neuropsychiatric disorders. Many studies have investigated how 
abnormalities in the OXT system give rise to symptoms and socio-cognitive deficits many 
patients with neuropsychiatric disorders exhibit. Understanding the patho-physiology of        
these disorders enables the development of more efficacious therapeutic agents which target     
the abnormalities and give rise to less adverse effects.  
In this review we summarize the literature available to date about the role of OXT in 
schizophrenia, autism spectrum disorders (ASD), addiction to drugs of abuse and anorexia 
nervosa (AN). Although these disorders are very Sept.arate and different entities, they all have 
something common in their pathology; they are associated with deranged OXT systems. 
Although many studies have been conducted to determine the exact role of OXT in these 
disorders and how OXT can be used to treat these disorders, research is still in its infancy. 
Further research is required to be able to standardize OXT as a therapeutic agent, determine       
its effects and safety, both in short-term and long-term use.  
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Introduction                                                                                                                         
Oxytocin (OXT) is a polypeptide composed of nine amino acids. Its synthesis occurs in the 
magnocellular cells of the supraoptic (SON) and paraventricular nuclei (PVN) of the 
hypothalamus. It is stored and released from the posterior pituitary. Smaller quantities of OXT 
are synthesized by the parvocellular cells of the PVN of the hypothalamus1.Other regions     
which may synthesize OXT are the bed nucleus of the stria terminalis, lateral amygdala and      
the medial preoptic area1–3.  
The role of OXT in humans is extensive; it is involved in pregnancy and labor, lactation and 
response to stress. It is also cardio-protective and plays a role in the cardiovascular system.         
It is also famous for its role in pair bond formation, parental care as well as social recognition.  
Since OXT has been found to exert an anxiolytic effect as well as play an important role             
in recognizing emotions and social behavior, it is thought that it also plays a role in neuro-
psychiatric disorders characterized by deficits in social cognition and increased stress and 
anxiety. Such neuropsychiatric disorders include schizophrenia, autism Spectrum Disorders 
(ASDs), drug addiction and anorexia nervosa (AN).   
Schizophrenia 
Schizophrenia is a psychotic disorder which affects an estimated 51 million people all over the 
world4. As shown in Table 2, the symptoms of schizophrenia are classified into two categories; 
positive symptoms and negative symptoms, with impaired emotional face recognition being 
heavily implicated in the disorder5. Being a very complex disorder, it is still vaguely under- 
stood, however one possible cause of schizophrenia is the dysregulation of chemical systems,  
one of which being the OXT system4,6. The extent to which the OXT system is disrupted affects 
how severe the symptoms are. For this reason, administration of OXT to schizophrenic patients  
to counteract the imbalance is deemed as a possible treatment for schizophrenia4. 
Current anti-psychotic drugs relieve the positive symptoms, but are not very effective in 
improving the negative symptoms. However, new treatment involving OXT can help improve  
the negative symptoms associated with schizophrenia since OXT is involved in all symptom 
domains4. 
 
Symptoms of Schizophrenia 
Positive Symptoms Negative Symptoms 
Hallucinations Social withdrawal 
Delusions Inability to feel pleasure 
Lack of Coordination (dysmetria) Cognitive impairments i.e. disorganized thinking, 
impaired memory & lack of attention 
Eye tracking dysfunction Speech disturbances 
Saccadic Eye movements General lack of drive 
Table 1: Classification of symptoms exhibited by schizophrenic patients (adapted from4,7) 
Schizophrenia is caused by the combination of a disrupted dopaminergic system, a 
malfunctioning amygdala and dysregulation in the OXT system8. Further research shows         
that hypoactive N-methyl- D-aspartate (NMDA) receptors also play a role in bringing about     
the negative symptoms associated with schizophrenia4,9 
Emotions and social behavior are mainly controlled by a part of the brain called the amygdala, 
which is found near the front end of the hippocampus. It serves as an integration center for 
various sensory inputs such as sense of smell, sight, taste10 and also fear8.  
The amygdaloid complex is made up of three subnuclei; the medial group, the basal-lateral group 
and the central-anterior group10. It forms several networks with the ventral tegmental area and the 
closely positioned nucleus accumbens; two dopaminergic structures. The interactions between  
the amygdala and the dopaminergic structures   are important for the proper identification of 
stimuli8.   
In animal studies, OXT receptors (OXTR) have been found in abundance in the central-anterior 
group of the amygdaloid complex, as well as in the basal-lateral and medial group, however in 
much smaller amounts. Some OXTRs have also been identified in   the hippocampus and the 
nucleus accumbens8. The exact pattern of distribution of OXTRs in the human brain has not     
yet been determined11. However, studies have found that the administration of intranasal OXT    
is associated with a decrease in amygdalar activation following exposure to a socioeconomic 
stimulus which elicits fear11,12. This suggests a link between OXT and the amygdala.  
Hyperactivity of the amygdaloid complex is associated with social impairment and increased 
social angst; both characteristics of schizophrenia. Abnormalities in the amygdala impair the 
detection of stimuli and cause it to respond inappropriately, thus bringing about social 
impairments. For instance, schizophrenic patients are not able to respond adequately to harmful 
situations because of the abnormally low activity of their amygdala. However, they may respond 
aggressively to non-harmful situations because of the abnormally high activity of the mygdala13. 
Low activity of the amygdala means that there is little amygdalar response to a stimulus, whereas 
high activity of the amygdala means that the amygdalar response to a stimulus is strong13. 
OXT has been found to be anxiolytic, i.e. it helps to reduce stress and anxiety and increases 
relaxation13–15. A higher concentration of OXT in the plasma is associated with a decrease in    
the plasma norepinephrine concentration, a decrease in the amount of vasoconstriction as well   
as a reduction in the sympathetic response in reaction to stress; all of which are mechanisms 
which contribute to the anxiolytic effect of OXT15. The anxiolytic property of OXT is also 
thought to  be brought about by the increase in transmission of gamma Aminobutyric acid 
(GABAergic) inhibitory interneurons found in structures belonging to the limbic system. A 
decrease in the number of GABAergic inhibitory interneurons may be part of the patho-
physiology of oxytocin-related social cognition impairment in schizophrenic patients8. 
A post-mortem study showed that the schizophrenic brain has a lesser amount of OXTRs in      
the temporal cortex compared to that of a healthy human brain, as well as a decreased binding 
affinity of OXTRs in the vermis16. This defect in the OXTR contributes to the pathophysiology    
of schizophrenia. 
Schizophrenic patients have a plasma concentration of OXT which is lower than that found        
in healthy individuals. The lower the concentration of OXT, the more severe the negative 
symptoms of schizophrenia are, as measured on the Positive and Negative Syndrome Scale 
(PANSS)17 18. Single nucleotide polymorphisms (SNPs) in the OXT and OXTR genes modulate 
an effect on the extent to which the symptoms of schizophrenia are severe4. Also, there is a 
correlation between the size of the OXT gene and the size of the amygdala12, which is found       
to be 6% smaller in volume in schizophrenic patients compared to healthy individuals8. 
Dopamine and OXT are also related; dopamine is thought to have a role in the release of OXT 
from the paraventricular nucleus (PVN). Furthermore, antagonizing dopamine transporters    
leads to a decrease in both the expression and the affinity of OXTRs8. Schizophrenic patients    
are thought to have an imbalance in the dopamine system, such that there is a surplus of 
transmission of dopamine in the mesolimbic pathway,  and a lack of transmission of dopamine   
in the pre-frontal cortex4. 
OXT as a Supplement for Anti-Psychotic Drugs 
Most of the antipsychotics currently being used to treat schizophrenic patients, i.e. the typical 
antipsychotics, are dopamine receptor (D2) antagonists. They are based on the dopamine 
hypothesis of schizophrenia described earlier. The problem with these typical antipsychotics       
is that while they improve most positive symptoms, they are not capable of improving the 
negative symptoms4. They have a very high affinity to D2 receptors, and as a result, their binding 
is not limited only to the limbic system, leading to many side effects, such as tremors as seen in 
Parkinson’s disease19.  
Other atypical antipsychotic drugs are more effective at improving positive and, to a lesser 
extent, negative symptoms4, as well as bring about less side effects. Having a lower affinity      
for D2 receptors, and an affinity for D3 and D4 receptors which are solely found in the limbic 
system, these atypical antipsychotics are constricted to work in the parts of the brain which       
are involved in schizophrenia19.  
Irrespective of the atypical antipsychotics being able to help relieve negative symptoms, both 
typical and atypical antipsychotics are unable to improve social cognition in schizophrenic 
patients20. Recent studies trying to find an ideal therapeutic for improving social cognition          
in schizophrenic patients have been focusing on the administration of intranasal OXT as a 
supplement to antipsychotic drugs21.  
Although OXT can be used as a therapeutic for all patients, patient gender should be taken into 
consideration in order for effective management of OXT. Since the OXT system is regulated by 
estrogen and progesterone, changes in the levels of these hormones throughout the menstrual 
cycle in females may be associated with changes in the presentation of symptoms18.   
When intranasal OXT was administered to healthy individuals, functional magnetic resonance 
imaging (fMRI) showed a reduction in the activation of the amygdaloid complex when 
participants were exposed to fearful faces, and an increase in the activation of the amygdaloid 
complex when participants were exposed to happy faces18. Increased activity in the amygdala 
may be the reason why schizophrenic patients perceive neutral or non-harmful faces as being 
threatening22.  
Similar studies were also carried out on male schizophrenic patients9. Patients chosen were those 
who had been receiving stable doses of antipsychotics for at least four weeks. Any patients who 
were receiving treatment for mood swings were excluded from the study since there is still not 
enough knowledge on the relationship between drugs which stabilize moods and the OXT 
system20. The patients were administered a maximum of 40 International Units (IU) of intranasal 
OXT for 3 consecutive weeks, during which they were monitored. This study conducted by  
Feifel et al. showed improvement of both positive and negative symptoms after the third week   
of intranasal OXT administration23. Furthermore, after the third week of the study, participants 
underwent the California Verbal Learning Test and the Letter Number Sequence test in order to 
examine if the participants experienced any loss of memory as a result of intranasal OXT 
administration. Results showed that the participants who had been receiving intranasal OXT did 
not experience any memory loss. Also, participants who had been administered intranasal OXT 
did better on two subtests than participants who had been administered a placebo23. 
Results of a randomized, double-blind, placebo-controlled experiment which studied the effect  
of intranasal OXT as an adjunct to risperidone for a period of 8 weeks also showed that intranasal 
OXT ameliorated the positive symptoms of schizophrenia. Statistics show that OXT may also 
have an ameliorating effect on negative symptoms and total psychopathology scores however 
these effects are unlikely to be clinically significant11,24. 
A similar study conducted by Woolley, Chuang et al. aimed to find the effect of intranasal OXT 
on different aspects of social cognition; mainly on automatic social cognition and on controlled 
social cognition20. Automatic social cognition is described as being ‘reflexive’, due to its 
immediate and unconscious nature. On the other hand, controlled social cognition is described   
as being ‘reflective’ since it involves conscious thinking and occurs over a longer period of    
time than automatic social cognition 20. 
The participants of this study included both schizophrenic patients, as well as healthy individuals 
as controls. After participants of the study had randomly received 40 IU of intranasal OXT or    
of saline solution as a placebo, tests regarding social cognition were carried out. The “Reading 
the Mind in the Eye Test” (RMET) together with Emotional Evaluation Test (EET) and Simple 
Sarcasm Exchanges (SSR) test, was used to evaluate the effect of intranasal OXT on automatic 
social cognition.  Social Inference Enriched (SI-E) test was used to evaluate the effect of 
intranasal OXT on controlled social cognition20.  
Results from this study show that intranasal OXT had a positive, ameliorating effect on 
controlled social cognition in schizophrenic patients, compared with the healthy controls. The 
results also show that intranasal OXT did not have any effect on automatic social cognition in 
both the schizophrenic patients and the healthy individuals. Since controlled social cognition      
is associated with an improved quality of life, this study affirms the use of intranasal OXT as       
a supplement for antipsychotic drugs used to treat schizophrenic patients20  
The positive ameliorating effect intranasal OXT brought about on controlled social cognition     
in schizophrenic patients is probably to do with the fact that OXT improves working memory,  
helps patients remain interested in social communication and also enhances non-social cognition, 
resulting in the augmentation of social cognition. While the reason why OXT was ineffective in 
ameliorating automatic social cognition remains undetermined, the results concerning healthy 
individuals were probably due to the high concentrations of intranasal OXT used in the study 
(40IU), which led to OXT binding to both OXT and vasopressin receptors; the effects of which 
counteracted each other20.  
OXT as an Anti-Psychotic Therapeutic Drug 
A study carried out by Caldwell, Stephens et al. aimed to prove that OXT has natural properties 
of antipsychotic drugs. The experiment was carried out on laboratory mice which had the OXT 
gene switched off and on laboratory mice which had a functional OXT gene9. The mice were 
administered doses of amphetamine (Amp), apomorphine (Apo) and phencyclidine (PCP) in 
order to induce a reduction in the Prepulse Inhibition (PPI) of the startle reflex; a reduction seen 
in schizophrenic patients9,20. Apo is a D1 and D2 receptor agonist; Amp brings about the release 
of dopamine and then prevents its reuptake, and PCP is an N-methyl-D-aspartate receptor 
(NMDAr) antagonist9. 
Results of this study show that there was a greater change in the PPI of the startle reflex in the 
knockout mice than in the mice with the switched-on OXT gene. This implies that OXT may 
indeed have a role as a natural antipsychotic as it prevents alterations of PPIs when chemical 
systems are disrupted. It also gives rise to the possibility of OXT being used an anti-psychotic    
to treat disruptions in PPIs9. Furthermore, the greatest reduction in PPI was observed in the 
knockout mice which were administered PCP. PCP affects the glutamatergic system, which as 
explained above, is a cause for the negative symptoms of schizophrenia if it is low in activity. 
This observation leads to the hypothesis that there is a link between OXT and the glutamatergic 
system9. However, more research has to be done in order to identify and establish this link.  
Schizophrenic patients also experience a low latent inhibition (LI)25,26. LI refers to the process   
by which our brain takes more time to process and give meaning to familiar stimuli than it does 
for unfamiliar stimuli26. This process is important to allow human beings to adapt to new 
situations. People having a low LI treat familiar situations as if they were unfamiliar. Since LI    
is targeted by anti-psychotic drugs, and OXT is thought to have anti-psychotic properties, it is  
likely that OXT can be used as a possible treatment for low LI. This was investigated in a study 
conducted by Feifel, Shilling et al. Brown Norway rats were used in this study to see how they 
would react to unpleasant flavored water, depending if they had been pre-exposed to the flavored 
water or not. The rats were either administered a saline solution as a control, or else they had 
different doses of OXT injected into their peripheral circulation26.  
Results showed that there is a correlation between OXT and a high LI. In fact, rats which had 
previously been exposed to the unpleasant flavored water and had been administered OXT, drank 
more flavored water than those rats which had not been previously exposed to the unpleasant 
flavored water26. This indicates that OXT targeted directly the LI; it increased the loss of the 
aversive taste brought about by the pre-exposure to the unpleasant water without actually 
changing the unpleasant taste itself26.  Also, the dose of OXT which had the best results in 
increasing LI was the lowest dose out of the three used; 0.02mg/kg. This is probably because 
when higher doses were used, OXT ended up binding to vasopressin receptors, bringing about     
a counteractive effect26. 
Schizophrenia is a very complex disorder involving various factors including OXT. OXT plays    
a very important role in schizophrenia. OXT plays a role in its etiology in its severity and also in 
its treatment. Although there is still a lot of research to be done, it is evident that administering 
OXT to schizophrenic patients will be a huge step towards improving their overall health and 
lifestyle.  
Autism Spectrum Disorder                                                                                                   
Autism is a developmental disorder which is characterized by a multitude of shortcomings in 
social behavior27. Approximately 1% of the worldwide population is affected by this genetic 
disorder28; with every 1 in 1000 individuals being autistic27. It is a disorder which typically 
affects more males than females, with a ratio of males: females of 5:129.Autism is considered     
to be a spectrum disorder because its symptoms’ severity may vary over a wide range in   
different individuals identified with autism28. 
Although it has been established by various studies that genetics play a vital role in the etiology 
of autism, different gene mutations have been identified in different cases of autism. In fact,   
each gene mutation identified as a cause of autism is associated with no more than 1 to 2% of 
autism spectrum disorder (ASD) cases30,31. 
According to the Diagnostic and Statistical Manual of Mental Disorders, ASD symptoms are 
classified into two domains which comprise symptoms associated with impairment in social 
communication and those associated with restricted and repetitive interests and behaviors28,29.    
In order for an individual to be diagnosed as autistic, the above mentioned symptoms must be 
observed in the individual at an early age during childhood28. 
Atypical antipsychotics are the current treatment given to ASD patients. Although these drugs 
have been proved to ameliorate symptoms such as hyperactivity and tantrums, they do not    
target the main deficits in social behavior associated with autism28.  
New studies have been focusing on the neuropeptide OXT, which has been largely associated 
with social behavior. As well as trying to determine the role of OXT in the etiology of ASDs, 
studies are also focusing on the role of OXT as a potential therapeutic for ASDs31. 
Autistic individuals exhibit a variety of abnormalities; they exhibit mutated genes, abnormal 
brain structure and composition as well as altered levels of neuropeptides such as OXT. There    
is such a wide range of clinical presentations of autism that no single factor can be pinpointed    
as a cause of this developmental disorder.  
Autistic patients tend to have an enlarged brain as well as abnormal cellular composition of the 
brain tissue. Abnormalities of the cerebellum are largely associated with the clinical presentation 
of ASDs. Such abnormalities include underdevelopment of the cerebellar vermis, cerebellar 
hemispheres as well as a decrease in the amount of Purkinje cells in the cerebellum. Cerebellar 
activation in autistic individuals is in excess during straight forward skills which require little 
cognitive ability. However, it is somewhat reduced when the individual is performing tasks which 
require great cognitive ability, accuracy and attention31. Mutations in the Tuberous Sclerosis 
(Tsc1) and neuroligin-3 (Nlgn3) genes are associated with ASDs. Deletions of the latter gene   
are related to blocked metabotropic glutamatergic receptor-dependent long term depression 
(MGluR-LTD) at synaptic junctions between Purkinje cells and parallel fibers. This blockage     
in MGluR-LTD is related to the deficiencies in motor coordination seen in autistic individuals31 
Abnormal cellular composition of the frontal and temporal lobes of the cerebral cortex is often 
identified in autistic individuals.  These brain regions are associated with social and language 
development, therefore malformations of these regions are often considered to play a role in the 
pathological physiology of ASDs31,32. Other brain regions which exhibit abnormalities in ASDs 
are the amygdala and the hippocampus, both of which are associated with social behaviors. 
Whilst some studies concluded that the abnormalities include an increase in the volume of these 
subcortical brain regions, others concluded that autistic individuals exhibit a decrease in the 
volume of the amygdala and hippocampus31. 
There is a high concentration of OXTRs in the amygdala and so any mutations in OXT and 
OXTR genes are thought to account for the deficits in social behavior observed in autistic 
individuals. In fact, mutations in the OXTR gene and the CD38 gene, thought to be involved      
in the release of OXT, have been associated with ASDs33. However not all studies found a 
correlation between SNPs in the above-mentioned genes and ASDs33,34. The reason for this 
discordance is probably due to the diversity between the individuals who participated in this 
study and those who participated in the studies which support the hypothesis33.    
A study conducted by Gregory et al. 2009 suggested that the gene for OXTR is silenced in 
autistic individuals. The silencing of the gene is due to the excessive methylation it undergoes 
due to a mutation33.                                                                             
Studies show that autistic individuals do not undergo the normal developmental increase in OXT 
levels. In fact, autistic individuals exhibit depressed levels of OXT in the bloodstream27,35–37. 
Findings which show elevated levels of the precursor of OXT, OXT-X, in the bloodstream offer 
the possibility that the reason why autistic individuals exhibit lower levels of OXT in the plasma 
than normal is because of a malfunction occurring in the synthesis of OXT 36. 
An inverse relationship between plasma OXT levels in autistic individuals and their social 
behavior was observed, such that those autistic individuals who had the highest plasma OXT 
levels exhibited the worst forms of social behavior deficits27,37. Healthy individuals who have 
higher levels of OXT have better social abilities than healthy individuals with lower levels of 
OXT. Thus, the effect of OXT on social abilities in autistic individuals is opposite the effect it 
has on healthy individuals. Defects in the gene encoding OXT or in the processing of OXT   
could account for the decreased plasma OXT concentration in autistic patients, whereas defects in 
the gene encoding OXTR could account for the positive correlation between high OXT levels and 
worse social behavior deficits37.  
OXT may also serve as the link between the social capacities of autistic children and the autistic 
traits exhibited by their parents, but further research is required37.   
 
OXT as a Potential Therapeutic for Autistic Individuals 
In an experiment conducted by Andari, Duhamel et al. individuals were asked to play a computer 
game of ball-tossing between 4 participants, three of which were fictitious players who were 
given the roles of good, bad and neutral players. The game was played with a healthy subject, an 
autistic patient under a placebo and an autistic patient who was administered OXT. Similarities 
were observed between the healthy subject and the patient who was administered OXT, in that 
they were both biased in throwing the ball towards the good player. The patients who were   
given the placebo showed no marked bias to any one of the players. Also, patients who were 
administered OXT developed more trust towards the good player rather than the bad player, 
whereas patients under the placebo showed no difference in their attitudes towards the good and 
the bad players. Patients given the OXT infusion were able to distinguish between the players 
who reciprocated the ball toss and the players who did not reciprocate the ball toss. This shows 
that OXT, apart from increasing trust, also increases the motivation to interact socially, which 
subsequently helps to improve the learning process36 
Another experiment conducted to investigate how OXT modulates the way autistic patients 
looked towards human faces showed that OXT increased to a certain extent the fixation of the 
patient on the eye region and decreased the saccadic eye movement associated with social    stress 
and anxiety. This may be due to the suppressive effect OXT has on the activation of the 
amygdala, thereby reducing the response to fear36. 
OXT is also associated with the repetitive behavior observed in autistic individuals38.  15 autistic 
off-medication adults were given continuous infusions of either OXT or of a placebo. The 
infusions were administered over 4 hours, during which the dose of the infusion was gradually 
increased, with the subjects being closely monitored to ensure their wellbeing. Throughout the 
administration of the infusions, at every hourly interval, the subjects were observed for six 
different; the necessity to know, repetitiveness, ordering, necessity to tell or ask, self-harm and 
touching. The participants were given a rating based on how they scored for each behavior.     
The same experiment was carried out 2-3 weeks later with the same 15 participants38. 
Results showed that generally, participants given the OXT infusion exhibited a decrease in 
repetitive behavior as well as a decrease in the number of different repetitive behaviors. No 
decrease in repetitive behavior was observed in the placebo group; with 6 of the subjects 
exhibiting an increase in repetitive behavior. One subject who had received OXT exhibited        
an increase in repetitive behavior 38. It must be taken into consideration that this study was 
conducted on a small number of subjects and it did not include autistic children. Therefore, 
although its results support the use of OXT as a potential therapeutic in autistic individuals, it has 
several limitations38. 
Studies have shown that OXT not only increases the social cognition of autistic individuals but   
it also helps autistic individuals to retain more the social cognition33,39.  Studies investigating the 
performance of autistic individuals in the RMET before and after OXT administration showed 
that the participants who had been given OXT scored better on the RMET than those who had 
been given a placebo33,40,41. The study carried out on individuals aged more than 16 showed     
that the participants showed an improvement for items considered to be difficult40, whereas that 
carried out on individuals younger than 16 showed an improvement for items considered to be 
easy41. This may be because children and pre-teens can continue to improve on skills they have 
not yet fully mastered however developing adults are unlikely to continue improving skills they 
have already mastered 33. 
One of the mechanisms by which OXT may improve ASD social symptoms is by inhibiting the 
hypothalamic-pituitary-adrenal (HPA) axis and the amygdala on exposure to social stimuli. OXT 
may also interact with the dopaminergic pathway as well as several parts of the brain forming   
the social brain, thereby increasing the individual’s will to interact socially. A third possible 
mechanism is by enhancing the ability to detect social stimuli15,42,43. 
OXT is not labelled as an ASD therapeutic drug; however, it has been prescribed to autistic 
individuals as an off-label drug, with the aim of ameliorating the social deficits associated with 
ASDs 44.  
Human studies show that while OXT has been administered for long-term treatment to male 
patients without any adverse effects, there is hesitancy when it comes to prescribing OXT to 
autistic females. This hesitancy is probably due to the well- known effect OXT has on lactation 
and uterine contractions44. However a case report documented by Kosaka, Munesue et al.    
shows the marked improvement in the aggressive, self-harming and irritable behavior of a 16-
year-old girl who had been receiving long-term treatment with intranasal OXT infusions. No 
signs of a disrupted menstrual cycle and ejection of milk were recorded in this case report44. 
Nevertheless, an animal study conducted by Bales et al. (2012) shows the possibility of adverse 
effects associated with long-term OXT therapy. While intranasal infusions of OXT initially 
improved social behavior in prairie voles, over time, deficits in the prairie voles’ partner 
preference behavior started being observed, suggesting that it might not be all that safe to use 
OXT as a long-term therapeutic33.  
Further research conducted on larger groups of patients needs to be conducted in order to 
establish further the efficacy and safety of OXT therapy for ASD patients, as well as standardize 
a method of administration, which dosages are safe to use and the optimal duration of therapy. 
Determining which patient groups more likely to benefit from OXT treatment would be ideal45.  
Although ASDs are complex, multifactorial disorders, repetitiveness and deficits in social 
behavior exhibited by autistic individuals can be targeted using OXT. Further research must      
be carried out in order to fill in the gaps in current research and have a better understanding of     
how OXT can be used as a therapeutic drug for ASDs without causing any harmful effects. 
OXT & Addiction 
Addiction to alcohol and illicit drugs is a worldwide problem. According to a study carried out  
by Gowing, Ali et al. the number of people addicted to alcohol estimates to 240 million people 
worldwide. The same study shows that the number of intravenous drug users (IVDUs) adds up   
to approximately 15 million people worldwide 46 
Alcohol and drug addicts tend to exhibit deficits in social behavior. OXT, being largely affiliated 
with social behaviors, is thought to play a role in the development of tolerance and addiction. 
Another hypothesis supporting this premise is that negative experiences endured in early 
childhood may affect the development of the OXT system47,48. Furthermore, the OXT system     
is linked to the dopamine system, as well as the immune system and the autonomic nervous 
system; systems which are abnormal in addicts 48. 
The Role of OXT in bringing about the Prosocial Effects of Drugs 
OXT plays a role in bringing about some of the prosocial, rewarding effects of drugs of abuse49. 
The prosocial effects brought about by the intake of low doses of 3,4-methylenedioxy-methamp-
hetamine (MDMA/ ecstasy) are thought to be due to the release of OXT from the SON and    
PVN of the hypothalamus following activation of the 5HT1A receptor. In fact, MDMA users are 
found to have higher plasma OXT levels than normal49,50. Dehydration and high temperatures 
seem to promote the release of OXT from the SON and PVN of the hypothalamus51,52. In fact,    
it has been observed that people who make use of MDMA prefer to do so under warm 
conditions52,53.  
OXT is greatly associated with the mesolimbic dopaminergic system. The interaction of OXT 
with the DOPA system in the nucleus accumbens is a component in the development of both 
social reward, such as pair bonding, as well as drug reward49,52. An experiment carried out on 
prairie voles by Anacker & Ryabinin (2010) demonstrated that although the same pathway is 
involved in social and drug reward, there is preference to social reward over drug reward52,54. 
People with difficult pasts have a higher tendency of taking drugs and alcohol than normal.    
This may be due to the fact they do not have stable bonds with other individuals making them 
more susceptible to becoming addicts to drugs and alcohol52  
The Effect of Drugs of Abuse on the Oxytocin system 
Animal studies have shown that chronic use of drugs of abuse is associated with abnormalities   
in the endogenous OXT signaling system55. While acute administration of cocaine resulted in    
an increased concentration of OXT hormone in the dorsal hippocampus of rodents56, chronic 
cocaine administration resulted in decreased OXT concentration in the hippocampus57 and an 
increased amygdalar OXTR signaling58. Different drugs of abuse affect different parts of the 
brain 55. Chronic morphine administration resulted in low OXT concentrations in the 
hypothalamus and increased receptor binding in the anterior olfactory nucleus, amygdala, 
piriform cortex and medial Sept.tum55,59. Chronic alcohol intake was also associated with 
decreased OXT levels55. On the other hand, ecstasy was associated with increased plasma      
OXT levels60 and increased hypothalamic OXT messenger ribonucleic acid (mRNA) levels61.     
It must be taken into consideration that peripheral blood OXT levels do not necessarily reflect 
OXT levels in the CNS52 
Addiction is considered to be a form of dysfunctional learning62, and since studies have shown 
that OXT inhibits learning and memory consolidation, it may have a role in reversing drug 
addiction55. Early studies conducted by Kovacs et al. (1985) showed that OXT inhibits the 
development of acute tolerance to morphine, and that the degree of inhibition depends on the 
dose of OXT57,63. Later studies have shown that OXT also inhibits the development of chronic 
tolerance to morphine in a dose-dependent manner57. The same OXT-tolerance reducing       
effect was observed in studies conducted using alcohol as a drug of abuse55.  
Furthermore, OXT not only inhibits tolerance development but also decreases the physical 
dependency on drugs57. OXT also inhibits the development of tolerance to cocaine as well as 
promotes cocaine sensitization 49,57. OXT also plays a role in reducing cocaine-seeking behavior 
by increasing the phosphorylation of the GluA1 subunit of the glutamate receptor in multiple 
brain regions55,64. Also, there seems to be a physical interaction between the glutamate receptor 
and OXTR55,64 .  
The Role of OXT as a therapeutic agent for addiction 
As discussed previously, OXT has a role in decreasing the development of tolerance, reversing 
tolerance and also relieving drug withdrawal effects. An animal study carried out by Cui, Bowen 
et al. 2001 on cannabis-dependent rats demonstrated how administration of lithium chloride 
promoted the expression of Fos protein in OXT-immunoreactive neurons located in the SON   
and PVN of the hypothalamus, and in doing so increased the expression of OXT mRNA in the 
SON and PVN of the hypothalamus49,65. The resultant increase in plasma OXT levels was 
correlated with a decrease in the characteristic cannabinoid withdrawal symptoms such as panic 
and confusion49,65. When an OXT antagonist was administered 1 hour prior to lithium injection, 
the rats still exhibited withdrawal symptoms. The same withdrawal symptoms were observed 
when the rats were administered an OXT antagonist without lithium treatment65. 
Systemically delivered OXT has been shown to reduce the methamphetamine-induced Fos-
protein expression in the core of the nucleus accumbens52,66. Further, intracerebroventricular 
(ICV) OXT can also be used to prevent methamphetamine drug relapses brought on by stress. 
OXT brings about its anxiolytic effect by antagonizing corticotrophin-releasing factor (CRF). 
CRF brings about the stress response through activation of the hypothalamus pituitary axis.  
Since OXT has the potential to dampen the response to stress it may be used to prevent 
individuals from relapsing to substance abuse in times of stress52,67. 
OXT has a significant role in the underlying mechanisms by which addictions develop. Current 
studies show that there is a lot of potential for OXT to be used in the treatment of addictions. 
Further research is required to investigate any adverse effects of exogenous OXT administration. 
Also, if OXT is to be used as a preventative measure to decrease susceptibility to addiction, 
research must extend beyond the physiology behind addiction and look into philosophical    
issues such as the consequences it may have on society52. 
OXT & Anorexia Nervosa 
Anorexia nervosa (AN) is an eating disorder that affects both males and females. It is most 
common amongst teenagers and young adults. AN leads to weight loss and muscle wasting.        
It is also a psychological illness that can be fatal if not taken care of. In fact, apart from causing 
the affected individuals to have a false perception of the way their body looks, AN is also 
associated with increased stress and anxiety, as well as changes in social behavior68. 
It is not surprising that OXT, being highly associated with stress and social behavior, is thought 
to be involved in the pathophysiology of AN69. Furthermore, OXT is thought to have a role in 
inducing satiety, so it is possible that OXT also plays a role in regulating food intake. Several 
studies have been conducted to determine whether or not AN patients exhibit alterations in    
OXT levels.  
While treatment of AN is by far very challenging, determining the role of OXT in the patho-
genesis of this illness can lead to the development of novel therapies that may aid in recovering 
AN patients.  
OXT Levels in Anorexic Patients 
A study carried out by Demitrack, Lesem et al. (1990) investigated OXT levels found in CSF of 
anorexic patients. Results showed that the food-restricting anorexic patients exhibited lower 
levels of OXT in CSF than the bulimic and the control subjects70. After food intake, CSF levels 
of the restricting anorexic subjects returned to normal. There was also an increase in OXT levels 
in the CSF of bulimic anorexic subjects. The rise in CSF OXT levels was associated with food 
intake70. Another study showed that that patients suffering from AN exhibit less overnight 
secretion of OXT than healthy individuals71. 
Lawson, Holsen et al. (2012) aimed to identify whether or not there was a difference in OXT 
secretion in response to food intake between anorexic patients and healthy individuals.       
Results showed that the increase in peripheral OXT secretion following a meal was larger in 
anorexic patients compared to healthy subjects. It was also noted that anorexic patients who     
had gained weight exhibited a smaller increase in peripheral OXT secretion following food intake 
compared to those individuals who had not regained weight. This observation may be    due to the 
stimulation of α- MSH by leptin in adipose tissue. α- MSH works at the level of the 
hypothalamus and brings about inhibition of appetite. It decreases the secretion of OXT in 
plasma, while at the same time promoting the secretion of OXT in the CSF72. Furthermore, there 
was a correlation between decreased OXT secretions and decreased body fat and bone density 69.  
Apart from having decreased levels of OXT, patients suffering from AN also have a decreased 
level of prolyl endopeptidase (PEP) activity; the enzyme which cleaves OXT 73. 
The role of OXT as a therapeutic for Anorexia Nervosa  
OXT, being known to exert an anxiolytic effect seems to be a possible therapeutic agent for AN 
patients who have deranged OXT systems. Kim, Eom et al. (2015) studied the effect intra-nasal 
OXT has on anorexic patients. Results showed that patients who had been administered intranasal 
OXT were more able to detect emotions compared to those administered a placebo74. 
Another study showed that AN patient who received intranasal OXT exhibited less fixation on 
body image and images related to food. The effect of OXT in reducing attentional bias was larger 
in AN patients who had more socio-cognitive problems verging towards those of ASD patients75. 
Furthermore, another study observed that administration of the intranasal OXT to AN patients 
attenuated their eating disorder concern69. 
There are many underlying aspects of eating disorders such as anorexia nervosa. It has been 
established that OXT has a role in the pathophysiology of anorexia nervosa however further 
research must be carried out, especially since the studies are limited. Understanding the role of 
OXT in anorexia nervosa is important as it may give rise to new possibilities as to how anorexic 
patients are treated.  
Conclusion  
OXT is heavily implicated in the pathophysiology of the neuropsychiatric disorders discussed in 
this review. Although several studies have been conducted to determine the mechanism behind 
the dysregulation of the OXT system, there are still a lot of gaps in the knowledge we have so far 
about it. Further research is needed in order to establish the role OXT plays in these 
neuropsychiatric disorders and the role it may have as a therapeutic agent to target the social 
deficits and cognitive impairment associated with these disorders. Also, further research is 
required in order to determine how safe and efficacious OXT is as a therapeutic agent as well as 
to determine the best method of administration.    
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